Ascend metoprolol succinate ER tablets recalled for failed dissolution
Ascend Laboratories is recalling one lot of metoprolol succinate extended-release 25 mg tablets because they failed to meet dissolution specifications. This means the tablets may not break down and release the medication properly in the body. The affected lot was distributed nationwide.
From the FDA notice · Read the official notice ↗ · All Ascend Laboratories recalls
What to do
- Check if you take metoprolol succinate extended-release 25 mg from Ascend Laboratories (NDC 67877-590-01, lot #25140859, expiration Jan 2027).
- Contact your pharmacist or doctor if you have this medication.
- Do not stop taking your metoprolol without talking to your doctor first.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-590-01.
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
Details
- Units affected
- 17,304 100-count bottles
- Illnesses reported
- None reported
- Manufactured in
- 135 Us Highway 202 206 Ste 15, Bedminster, NJ, United States
- Classification
- Class II
- Recall number
- D-0547-2026
In the FDA's words
- Description
- Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-590-01. Failed Dissolution Specifications Lot # 25140859; Exp. Date: Jan 2027 Distribution: U.S. Nationwide Affected quantity: 17,304 100-count bottles
- Hazard
- Failed Dissolution Specifications
More from Ascend Laboratories
See all- Ascend amlodipine/olmesartan tablets recalled for failed dissolution
ModerateFDAOct 16, 2026